Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom
Open Access
- 1 February 2021
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (2), 332-334
- https://doi.org/10.3324/haematol.2020.266635
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)Annals of Oncology, 2019
- Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLBlood, 2019
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2018
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaCancer Discovery, 2017
- Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaCancer Cell, 2017
- CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapyCNS Oncology, 2015
- Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphomaCancer, 2010